MIF Antibody (932606) [Alexa Fluor® 594]

• Reactivity: Hu
• Applications: Flow
• Clone: 932606
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 594

MIF Antibody (932606) [Alexa Fluor® 594] Summary

• Immunogen: E. coli-derived recombinant human MIF
  Met1-Phe114
  Accession # P14174
• Specificity: Detects human MIF in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Intracellular Staining by Flow Cytometry 0.25-1 ug/10^6 cells

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for MIF Antibody (932606) [Alexa Fluor® 594]

• EC 5.3.2.1
• EC 5.3.3.12
• GIFmacrophage migration inhibitory factor
• GLIF
• Glycosylation-inhibiting factor
• L-dopachrome isomerase
• L-dopachrome tautomerase
• macrophage migration inhibitory factor (glycosylation-inhibiting factor)
• MIF
• MMIF
• Phenylpyruvate tautomerase

Background

MIF (or macrophage Migration Inhibitory Factor) was the first lymphokine/cytokine to be recognized in the pregenomics era (1, 2). Regardless, it is one of the least understood of all inflammatory mediators (1, 3). Human MIF is a 12.5 kDa, 115 amino acid (aa) nonglycosylated polypeptide that is synthesized without a signal sequence (4-7). Secretion occurs nonclassically via an ABCA1 transporter (8). The initiating Met is removed, leaving Pro as the first amino acid. The molecule consists of two alpha -helices and six beta -strands, four of which form a beta -sheet. The two remaining beta -strands interact with other MIF molecules, creating a trimer (2, 9, 10). Structure-function studies suggest MIF is bifunctional with segregated topology. The N- and C-termini mediate enzyme activity (in theory). Phenylpyruvate tautomerase activity (enol-to-keto) has been demonstrated and is dependent upon Pro at position #1 (11). Amino acids 50-65 have also been suggested to contain thiol-protein oxidoreductase activity (12). MIF has proinflammatory cytokine activity centered around aa’s 49-65. On fibroblasts, MIF induces, IL-1, IL-8, and MMP expression; on macrophages, MIF stimulates NO production and TNF-alpha release following IFN-gamma activation (13, 14). MIF apparently acts through CD74 and CD44, likely in some form of trimeric interaction (15, 16). Human MIF is active on mouse cells (14). Human MIF is 90%, 94%, 95%, and 90% aa identical to mouse, bovine, porcine, and rat MIF, respectively.

1. Norand, E.F. and M. Leech (2005) Front. Biosci. 10:12.
2. Donn, R.P. and D.W. Ray (2004) J. Endocrinol. 182:1.
3. Calandra, T. and T. Roger (2003) Nat. Rev. Immunol. 3:791.
4. Kozak, C.A. et al. (1995) Genomics 27:405.
5. Weiser, W.Y. et al. (1989) Proc. Natl. Acad. Sci. USA 86:7522.
6. Paralkar, V. and G. Wistow (1994) Genomics 19:48.
7. Wistow, G.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90:1272.
8. Flieger, O. et al. (2003) FEBS Lett. 551:78.
9. Philo, J.S. et al. (2004) Biophys. Chem. 108:77.
10. Sun, H-W. et al. (1996) Protein Eng. 9:631.
11. Stamps, S.L. et. al. (2000) Biochemistry 39:9671.
12. Nguyen, M.T. et al. (2003) J. Biol. Chem. 278:33654.
13. Sato, A. et al. (2003) Dev. Comp. Immunol. 27:401.
14. Bernhagen, J. et al. (1994) Biochemistry 33:14144.
15. Leng, L. et al. (2003) J. Exp. Med. 197:1467.
16. Meyer-Siegler, K.L. and P.L. Vera (2005) J. Urol. 173:615.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P14174()